Clinical Trial Update: Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B [Phase 2]

View source ↗

Summary

Phase 2 trial update on a next-generation recombinant Factor IX variant for Hemophilia B; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Next-Generation Recombinant Factor IX Variant (recombinant Factor IX variant)

Snippet

Sponsor: Catalyst Biosciences | Conditions: Hemophilia B | Phase 2 | Status: COMPLETED | Results posted: 2021-08-09